Suppr超能文献

HADHA是肺癌对铂类化疗反应的一个潜在预测指标。

HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.

作者信息

Kageyama Taihei, Nagashio Ryo, Ryuge Shinichiro, Matsumoto Toshihide, Iyoda Akira, Satoh Yukitoshi, Masuda Noriyuki, Jiang Shi-Xu, Saegusa Makoto, Sato Yuichi

机构信息

Department of Applied Tumor Pathology, GraKitasato University, Kanagawa, Japan.

出版信息

Asian Pac J Cancer Prev. 2011;12(12):3457-63.

Abstract

To identify a cisplatin resistance predictor to reduce or prevent unnecessary side effects, we firstly established four cisplatin-resistant sub-lines and compared their protein profiles with cisplatin-sensitive parent lung cancer cell lines using two-dimensional gel electrophoresis. Between the cisplatin-resistant and -sensitive cells, a total of 359 protein spots were differently expressed (>1.5 fold), and 217 proteins (83.0%) were identified. We focused on a mitochondrial protein, hydroxyl-coenzyme A dehydrogenase/3-ketoacyl-coenzyme A thiolase/enoyl-coenzyme A hydratase alpha subunit (HADHA), which was increased in all cisplatin-resistant cells. Furthermore, pre- treated biopsy specimens taken from patients who showed resistance to platinum-based treatment showed a significantly higher positive rate for HADHA in all cases (p=0.00367), including non-small cell lung carcinomas (p=0.002), small-cell lung carcinomas (p=0.038), and adenocarcinomas (p=0.008). These results suggest that the expression of HADHA may be a useful marker to predict resistance to platinum-based chemotherapy in patients with lung cancer.

摘要

为了确定一种顺铂耐药预测指标以减少或避免不必要的副作用,我们首先建立了四个顺铂耐药亚系,并使用二维凝胶电泳将它们的蛋白质谱与顺铂敏感的亲代肺癌细胞系进行比较。在顺铂耐药细胞和顺铂敏感细胞之间,共有359个蛋白点表达差异显著(>1.5倍),并鉴定出217种蛋白质(83.0%)。我们重点关注一种线粒体蛋白,即羟辅酶A脱氢酶/3-酮酰辅酶A硫解酶/烯酰辅酶A水合酶α亚基(HADHA),它在所有顺铂耐药细胞中均有增加。此外,对铂类治疗耐药的患者的预处理活检标本显示,在所有病例中,包括非小细胞肺癌(p=0.002)、小细胞肺癌(p=0.038)和腺癌(p=0.008),HADHA的阳性率显著更高。这些结果表明,HADHA的表达可能是预测肺癌患者对铂类化疗耐药的有用标志物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验